Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363110 | 0.91 | KDM4E (0.41) | CRHR1ALPLKDM4EALDH1A1GAA | |
| SCHEMBL3367536 | 0.87 | CRHR1 (0.49) | CRHR1ALPLKDM4ECNR1 | |
| SCHEMBL14206630 | 0.87 | CRHR1 (0.49) | CRHR1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL3364408 | 0.86 | CRHR1 (0.46) | CRHR1ALDH1A1HPGDDPP4CNR1 | |
| SCHEMBL3364750 | 0.86 | CRHR1 (0.48) | CRHR1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL3367005 | 0.85 | CRHR1 (0.45) | CRHR1ALPLKDM4ESLC6A3DPP4 | |
| SCHEMBL3846236 | 0.85 | CRHR1 (0.45) | CRHR1ALPLKDM4EALDH1A1DPP4 | |
| SCHEMBL3367449 | 0.84 | CRHR1 (0.46) | CRHR1ALPLKDM4EALDH1A1GAA | |
| SCHEMBL13617375 | 0.82 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL3366050 | 0.82 | CRHR1 (0.46) | CRHR1ALPLKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | claimed |
| EP-1656353-B1 | GABANERGIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2007753-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. Hoffmann-Roche AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007115966-A1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | CRHR1 96/4885ALPL 4323/4885KDM4E 1377/4885 |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885ALPL 4077/4885KDM4E 4580/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | CRHR1 1/4885ALPL 4071/4885KDM4E 4580/4885 |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | CRHR1 183/4885ALPL 2232/4885KDM4E 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.